DENTSPLY SIRONA: Hold Rating Amid Strong Performance and CFO Uncertainty

Needham analyst David Saxon has maintained their neutral stance on XRAY stock, giving a Hold rating on April 30.

David Saxon has given his Hold rating due to a combination of factors including DENTSPLY SIRONA’s recent financial performance and ongoing internal developments. The company’s first quarter of 2025 showed revenue and earnings that surpassed market expectations, which is a positive indicator. However, the guidance metrics remained stable or only slightly improved, suggesting limited immediate growth potential.
Additionally, while the company has made progress with restructuring and cost reduction efforts, which are beginning to positively impact the bottom line, there remains uncertainty due to the ongoing search for a new CFO. These mixed factors contribute to the decision to maintain a Hold rating, as the potential for further improvement is balanced by existing uncertainties.

Saxon covers the Healthcare sector, focusing on stocks such as RxSight, DENTSPLY SIRONA, and Staar Surgical. According to TipRanks, Saxon has an average return of -2.3% and a 34.03% success rate on recommended stocks.

In another report released on April 30, Piper Sandler also maintained a Hold rating on the stock with a $16.00 price target.